Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Pertuzumab for the treatment of ovarian cancer.

Langdon SP, Faratian D, Nagumo Y, Mullen P, Harrison DJ.

Expert Opin Biol Ther. 2010 Jul;10(7):1113-20. doi: 10.1517/14712598.2010.487062. Review.

PMID:
20465533
2.

HER-dimerization inhibitors: evaluating pertuzumab in women's cancers.

Kristjansdottir K, Dizon D.

Expert Opin Biol Ther. 2010 Feb;10(2):243-50. doi: 10.1517/14712590903514090. Review.

PMID:
20001562
3.

Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, Paton V, Lin CY, Januario T, Ng K, Strauss A, Kelsey S, Sliwkowski MX, Matulonis U.

J Clin Oncol. 2010 Mar 1;28(7):1215-23. doi: 10.1200/JCO.2009.22.3354. Epub 2009 Nov 9.

PMID:
19901115
4.

HER3 mRNA as a predictive biomarker in anticancer therapy.

Amler LC.

Expert Opin Biol Ther. 2010 Sep;10(9):1343-55. doi: 10.1517/14712598.2010.512003. Review.

PMID:
20695834
5.

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.

Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY.

J Clin Oncol. 2006 Sep 10;24(26):4324-32. Epub 2006 Aug 8. Erratum in: J Clin Oncol. 2008 Jun 1;26(16):2793.

PMID:
16896006
6.

Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.

Faratian D, Zweemer AJ, Nagumo Y, Sims AH, Muir M, Dodds M, Mullen P, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP.

Clin Cancer Res. 2011 Jul 1;17(13):4451-61. doi: 10.1158/1078-0432.CCR-10-2461. Epub 2011 May 13.

7.

Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.

Nagumo Y, Faratian D, Mullen P, Harrison DJ, Hasmann M, Langdon SP.

Mol Cancer Res. 2009 Sep;7(9):1563-71. doi: 10.1158/1541-7786.MCR-09-0101. Epub 2009 Sep 8.

8.

A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE.

Hodeib M, Serna-Gallegos T, Tewari KS.

Future Oncol. 2015;11(23):3113-31. doi: 10.2217/fon.15.266. Epub 2015 Nov 24. Review.

PMID:
26597460
9.

Pertuzumab: development beyond breast cancer.

Barthélémy P, Leblanc J, Goldbarg V, Wendling F, Kurtz JE.

Anticancer Res. 2014 Apr;34(4):1483-91. Review.

PMID:
24692675
10.

Pertuzumab: optimizing HER2 blockade.

Metzger-Filho O, Winer EP, Krop I.

Clin Cancer Res. 2013 Oct 15;19(20):5552-6. doi: 10.1158/1078-0432.CCR-13-0518. Epub 2013 Aug 13. Review.

11.

Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.

Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP.

Clin Cancer Res. 2009 Jun 15;15(12):4147-56. doi: 10.1158/1078-0432.CCR-08-2814. Epub 2009 Jun 9.

12.

Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.

Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, de Vries DJ, Eberhard DA, Lyons B, Lutzker SG, Johnson BE.

Clin Cancer Res. 2007 Oct 15;13(20):6175-81.

13.

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling.

Mullen P, Cameron DA, Hasmann M, Smyth JF, Langdon SP.

Mol Cancer Ther. 2007 Jan;6(1):93-100.

14.

[Pertuzumab and solid tumors: perspectives].

Barthélémy P, Leblanc J, Wendling F, Wissler MP, Bergerat JP.

Bull Cancer. 2014 Dec;101(12):1114-21. doi: 10.1684/bdc.2014.2026. French.

PMID:
25532690
15.

A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer.

Kaye SB, Poole CJ, Dańska-Bidzińska A, Gianni L, Del Conte G, Gorbunova V, Novikova E, Strauss A, Moczko M, McNally VA, Ross G, Vergote I.

Ann Oncol. 2013 Jan;24(1):145-52. doi: 10.1093/annonc/mds282. Epub 2012 Sep 20.

PMID:
23002282
16.

Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo.

Pohl M, Stricker I, Schoeneck A, Schulmann K, Klein-Scory S, Schwarte-Waldhoff I, Hasmann M, Tannapfel A, Schmiegel W, Reinacher-Schick A.

J Cancer Res Clin Oncol. 2009 Oct;135(10):1377-86. doi: 10.1007/s00432-009-0579-3. Epub 2009 Apr 2.

PMID:
19340455
17.

Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors.

Yamamoto N, Yamada Y, Fujiwara Y, Yamada K, Fujisaka Y, Shimizu T, Tamura T.

Jpn J Clin Oncol. 2009 Apr;39(4):260-6. doi: 10.1093/jjco/hyp006. Epub 2009 Mar 4.

18.

Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis.

Drucker AM, Wu S, Dang CT, Lacouture ME.

Breast Cancer Res Treat. 2012 Sep;135(2):347-54. doi: 10.1007/s10549-012-2157-7. Epub 2012 Jul 11. Review.

PMID:
22782294
19.

Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines.

Bijman MN, van Berkel MP, Kok M, Janmaat ML, Boven E.

Anticancer Drugs. 2009 Jul;20(6):450-60. doi: 10.1097/CAD.0b013e32832afc24.

PMID:
19369859
20.

Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.

Brockhoff G, Heckel B, Schmidt-Bruecken E, Plander M, Hofstaedter F, Vollmann A, Diermeier S.

Cell Prolif. 2007 Aug;40(4):488-507.

PMID:
17635517

Supplemental Content

Support Center